Lonza Announces New Mid-Term Guidance 2024 – 2028

17.10.2023 - At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

Lonza outlined five strategic priorities to support the company's ongoing commitment to sustainable value creation:

  • Continuous innovation to anticipate future customer needs
  • Collaboration built on early customer partnerships and customized solutions
  • Industry-leading service delivery, with a consistent focus on quality
  • Operational excellence and a culture of continuous improvement
  • Disciplined capital allocation strategy

The company has released its latest Mid-Term Guidance for the period 2024 to 2028, backed by the expansion of commercial growth assets and an ongoing commitment to operational excellence. The Mid-Term Guidance for 2028 comprises the following objectives: achieving a Compound Annual Growth Rate (CAGR) in sales of 11-13% in constant exchange rates (CER), maintaining a CORE EBITDA margin of 32-34%, and attaining a double-digit Return on Invested Capital (ROIC).

Albert M. Baehny, Chairman of the Board of Directors and CEO ad interim said, “Lonza maintains a sharp focus on executing its strategy and growth projects to capture opportunities and maintain industry leadership. Today, we shared in detail how our investment program will deliver in the mid-term. Our disciplined capital allocation strategy will support customers in bringing treatments quickly and securely to the market, whilst securing sustainable long-term value for our shareholders, stakeholders and society.”

Lonza has also increased its dividend payout range from 25–40% to a new range of 35–45%, showing confidence in its financial strength. Division strategic priorities in Lonza's biologics, small molecules, cell & gene, and capsule & health ingredient sectors were also shared at the Captial Markets Day. In these divisions, key strategic focuses encompass comprehensive lifecycle management, the enhancement of processes, establishing enduring customer partnerships, and distinguishing themselves through innovation and service offerings.

In Q3 2023, Lonza showed strength in CDMO (contract development and manufacturing organization) and commercial demand. Biotech funding constraints affected Biologics, and Capsules & Health Ingredients faced challenges in the US market. Lonza confirmed its 2023 Outlook with higher sales growth and improved CORE EBITDA due to the Moderna mRNA contract cancellation fee.

In 2024, business growth will be constrained by the higher 2023 baseline due to the Moderna loss and potential downsizing in the Kodiak Sciences business. Lonza anticipates a high twenties margin. More details on the 2024 Outlook will be shared by Lonza in January 2023.


Lonza AG

Muenchensteinerstrasse 38
4002 Basel